January 02, 2019 | Chip Kahn
Category: Financing, Medicare, Pharmaceuticals
The DC Federal District Court’s ruling to stop reforms to Medicare payment for drugs acquired under the 340B drug discount program is unfortunate because it undermines HHS efforts to cut drug costs and promote fairer payments.
The current HHS policy will ultimately lower drug costs for patients. It also benefits the vast majority of hospitals, including some 80 percent of rural facilities.
This ruling puts all those benefits at risk
We look forward to an appeals process that will recognize HHS authority to advance these program improvements.